The Mice Model Market was valued at USD 1.36 billion in 2023. It is projected to increase from USD 1.46 billion in 2024 to USD 2.68 billion by 2032, registering a CAGR of 7.8% during the forecast period.

Preclinical animal models remain the foundation of drug development

Preclinical animal models are essential tools in pharmaceutical and biotechnology research because they allow scientists to evaluate drug efficacy, toxicology, pharmacokinetics, and disease progression before human trials begin. The Polaris report highlights rising demand from pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations, all of which depend on mice models for drug development and testing. It also notes that these models are widely used across neurology, oncology, cardiovascular diseases, and genetic diseases.

This demand is closely tied to the growing prevalence of chronic diseases. The report states that conditions such as cancer, diabetes, cardiovascular disorders, and neurological diseases are fueling the need for reliable animal models that can mimic human genetics and physiology more closely. In practice, this makes mice models especially valuable for biomarker identification, therapeutic evaluation, and personalized medicine research.

Humanized mouse models are improving translational research

Among the most important innovations in the field are humanized mouse models, which are designed to carry human cells, tissues, or genes so researchers can observe disease behavior in a more clinically relevant environment. The report emphasizes that advances in genomic technologies and gene-editing tools such as CRISPR/Cas9, next-generation sequencing (NGS), and genome-wide association studies (GWAS) are accelerating the creation of genetically modified mice that better reflect human disease biology.

These advances matter because many diseases cannot be studied adequately in traditional models alone. Humanized mouse models help scientists examine immune responses, tumor progression, inherited disorders, and treatment resistance with greater precision. The report specifically links genomic progress to the development of personalized mouse models that mimic human genetic diversity, strengthening translational research and preclinical testing.

Cancer mouse models are central to oncology research

Cancer mouse models represent one of the most important application areas in the market. The report identifies oncology as a major application segment and states that it held a significant market share in 2023. This is driven by the global cancer burden and the need for specialized mice models that can replicate tumor heterogeneity, disease progression, and response to therapy.

The report further explains that personalized medicine in oncology increases the need for robust mouse models that can test patient-specific tumor responses. Advances in genetic engineering and tumor modeling are improving the sophistication and relevance of these models, which supports more accurate preclinical testing of cancer therapies. This makes cancer mouse models a critical bridge between laboratory research and human treatment development.

Market growth is being powered by technology and biomedical research investment

The Mice Model Market is also benefiting from rising investment in biomedical research. The report notes that funding from governments, academic institutions, and pharmaceutical companies is supporting the development of novel genetically engineered mouse models tailored to mimic human diseases more accurately. It also highlights partnerships in the industry, including a collaboration between InGenious Targeting Laboratory and the Shanghai Model Organisms Center to distribute validated mouse models across Europe and North America.

Another important growth driver is the expanding use of CRISPR/Cas9 and other genetic engineering methods, which make model development faster and more precise. The report specifically states that gene-editing technologies have revolutionized the creation of genetically modified mice, enabling more efficient modeling of complex diseases.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/mice-model-market

Key Companies

• Charles River Laboratories International, Inc.
• Cyagen Biosciences Inc.
• Envigo
• genOway S.A.
• Harbour Biomed
• Hera Biolabs
• Inotiv
• Janvier Labs
• Ozgene Pty Ltd.
• PolyGene
• Sage Labs
• Taconic Biosciences, Inc.
• The Jackson Laboratory
• Trans Genic Inc.

Regional outlook and segment structure

Geographically, North America dominated the market in 2023, supported by advanced research infrastructure, major pharmaceutical and biotechnology companies, strong government funding, and favorable regulatory frameworks. The report also indicates that the Asia-Pacific region is expected to grow strongly due to expanding biomedical research, increased healthcare investment, and the rising prevalence of chronic diseases.

The market is structured around model and service, end user, application, and region. Within models and services, the report includes outbred mice, inbred mice, genetically engineered mice, breeding, genetic testing, cryopreservation, and rederivation. This broad segmentation reflects how essential mice models have become across research workflows.

Conclusion

The Mice Model Market is evolving rapidly as research demand grows for more accurate, reproducible, and human-relevant models. Preclinical animal models continue to support early drug development, humanized mouse models are improving translational accuracy, and cancer mouse models remain central to oncology innovation. With strong backing from genomic technologies, chronic disease research, and pharmaceutical investment, the market is positioned for sustained expansion through 2032.

More Trending Latest Reports By Polaris Market Research:

Dialysis Catheters Market

Herpes Simplex Virus Treatment Market

Vascular Stent Market

Enzyme Immunoassay Market

Extracorporeal Membrane Oxygenation Machine Market

Wound Care Market

North America Gaucher Disease Treatment Market

CDMO Orthopedic Market